ImmunityBio Files 8-K: Board and Compensation Changes
Ticker: IBRX · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
TL;DR
ImmunityBio 8-K: Board shakeup and exec pay changes filed.
AI Summary
ImmunityBio, Inc. filed an 8-K on February 7, 2025, reporting changes in its board of directors and executive compensation arrangements. The filing details the departure of certain directors and the election of new ones, alongside updates to executive compensation. The company, formerly known as NantKwest, Inc., is based in San Diego, California.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can indicate internal shifts that may affect future performance or strategy.
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- February 7, 2025 (date) — Date of Report
- NantKwest, Inc. (company) — Former Company Name
- San Diego, California (location) — Principal Executive Address
FAQ
What specific items are being reported in this 8-K filing by ImmunityBio, Inc.?
This 8-K filing reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
When was this 8-K report filed by ImmunityBio, Inc.?
The report was filed on February 7, 2025.
What is the principal executive address of ImmunityBio, Inc.?
The principal executive address is 3530 John Hopkins Court, San Diego, California 92121.
What were ImmunityBio, Inc.'s former company names?
ImmunityBio, Inc. was formerly known as NantKwest, Inc., Conkwest, Inc., and ZelleRx Corp.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-02-07 16:52:21
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IBRX Nasdaq Global Select
Filing Documents
- d907316d8k.htm (8-K) — 22KB
- 0001193125-25-022776.txt ( ) — 137KB
- ibrx-20250207.xsd (EX-101.SCH) — 3KB
- ibrx-20250207_lab.xml (EX-101.LAB) — 17KB
- ibrx-20250207_pre.xml (EX-101.PRE) — 11KB
- d907316d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Date: February 7, 2025 By: /s/ Jason Liljestrom Jason Liljestrom General Counsel and Corporate Secretary -3-